1-20 of 54 Search Results for

*

Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma

Mir Lim, Maishara Muquith, Bernadette Miramontes, Magdalena Espinoza, David Hsiehchen
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1912–1916.
https://doi.org/10.1158/2767-9764.CRC-23-0025
Published: 21 September 2023
View article titled, Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma
Open the PDF for Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma in another window
Journal Articles

The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC

Joanne B Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A Masters, George R Blumenschein, Joe Y. Chang, Bo Lu, Adam P. Dicker, Jeffrey A Bogart, Yolanda I Garces, Samir Narayan, Clifford G. Robinson, Vivek S Kavadi, Joel S Greenberger, Christopher D Koprowski, James W. Welsh, Elizabeth Gore, Robert M MacRae, Rebecca Paulus, Jeffrey Bradley
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-23-0084
Published: 20 September 2023
View article titled, The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC
Open the PDF for The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Glenn J. Hanna, Anastasios Stathis, Elena Lopez-Miranda, Fabricio Racca, Doris Quon, Serge Leyvraz, Dagmar Hess, Bhumsuk Keam, Jordi Rodon, Myung-Ju Ahn, Hye Ryun Kim, Andreas Schneeweiss, Josep-Maria Ribera, Daniel DeAngelo, Jose Manuel Perez Garcia, Javier Cortes, Oliver Schönborn-Kellenberger, Dirk Weber, Pavel Pisa, Michael Bauer, Laura Beni, Maria Bobadilla, Raj Lehal, Michele Vigolo, Florian D. Vogl, Elena Garralda
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1853–1861.
https://doi.org/10.1158/2767-9764.CRC-23-0333
Published: 14 September 2023
View article titled, A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
Open the PDF for A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors in another window
Includes: Supplementary data
Journal Articles

Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy

Richard W. Davis, IV, Astero Klampatsa, Gwendolyn M. Cramer, Michele M. Kim, Joann M. Miller, Min Yuan, Cassandra Houser, Emma Snyder, Mary Putt, Sergei A. Vinogradov, Steven M. Albelda, Keith A. Cengel, Theresa M. Busch
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1810–1822.
https://doi.org/10.1158/2767-9764.CRC-22-0494
Published: 11 September 2023
View article titled, Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy
Open the PDF for Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy in another window
Includes: Supplementary data
Journal Articles

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Jiahui Liu, Wenqiang Yan, Huishou Fan, Jingyu Xu, Lingna Li, Chenxing Du, Xuehan Mao, Yuting Yan, Yan Xu, Weiwei Sui, Shuhui Deng, Shuhua Yi, Kenneth C. Anderson, Lugui Qiu, Dehui Zou, Gang An
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1770–1780.
https://doi.org/10.1158/2767-9764.CRC-23-0185
Published: 06 September 2023
View article titled, Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Open the PDF for Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment in another window
Includes: Supplementary data
Journal Articles

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Josep Tabernero, Philippe L. Bedard, Yung-Jue Bang, Maria Vieito, Min-Hee Ryu, Nathalie Fagniez, Mustapha Chadjaa, Christine Soufflet, Nina Masson, Anas Gazzah
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1662–1671.
https://doi.org/10.1158/2767-9764.CRC-23-0284
Published: 28 August 2023
View article titled, Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
Open the PDF for Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens in another window
Includes: Supplementary data
Journal Articles

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

H. Catherine Wilbur, Jennifer N. Durham, Su Jin Lim, Katrina Purtell, Katherine M. Bever, Daniel A. Laheru, Ana De Jesus-Acosta, Nilofer S. Azad, Bradley Wilt, Luis A. Diaz, Dung T. Le, Hao Wang
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1672–1677.
https://doi.org/10.1158/2767-9764.CRC-23-0230
Published: 28 August 2023
View article titled, Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
Open the PDF for Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors

Michael A. Carducci, Ding Wang, Christina Habermehl, Matthias Bödding, Felix Rohdich, Floriane Lignet, Klaus Duecker, Oleksandr Karpenko, Linda Pudelko, Claude Gimmi, Patricia LoRusso
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1638–1647.
https://doi.org/10.1158/2767-9764.CRC-23-0048
Published: 24 August 2023
View article titled, A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
Open the PDF for A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors in another window
Journal Articles

A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

Vina P. Nguyen, Katie M. Campbell, Theodore S. Nowicki, Nila Elumalai, Egmidio Medina, Ignacio Baselga-Carretero, Maggie L. DiNome, Helena R. Chang, Denise K. Oseguera, Antoni Ribas, John A. Glaspy
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1628–1637.
https://doi.org/10.1158/2767-9764.CRC-23-0145
Published: 23 August 2023
View article titled, A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
Open the PDF for A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme

Jason D. Lickliter, Jeremy Ruben, Ganessan Kichenadasse, Ross Jennens, Cecelia Gzell, Ralph P. Mason, Heling Zhou, Jennifer Becker, Evan Unger, Baldassarre Stea
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1607–1614.
https://doi.org/10.1158/2767-9764.CRC-22-0433
Published: 21 August 2023
View article titled, Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme
Open the PDF for Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme in another window
Journal Articles

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Myrto Moutafi, Georgia-Angeliki Koliou, George Papaxoinis, Panagiota Economopoulou, Ioannis Kotsantis, Maria Gkotzamanidou, Maria Anastasiou, Dimitrios Pectasides, Efthymios Kyrodimos, Alexander Delides, Evangelos Giotakis, Nikolaos G. Papadimitriou, Ioannis G. Panayiotides, Christos Perisanidis, Aileen I. Fernandez, Vasiliki Xirou, Christos Poulios, Eleni Gagari, Vesal Yaghoobi, Niki Gavrielatou, Saba Shafi, Thazin Nwe Aung, Andromachi Kougioumtzopoulou, Vassilis Kouloulias, Konstantinos Palialexis, Stavros Gkolfinopoulos, Areti Strati, Evi Lianidou, George Fountzilas, David L. Rimm, Periklis G. Foukas, Amanda Psyrri
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1514–1523.
https://doi.org/10.1158/2767-9764.CRC-23-0051
Published: 10 August 2023
View article titled, Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Open the PDF for Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Stephanie L. Alden, Mir Lim, Chester Kao, Daniel Shu, Amit G. Singal, Anne Noonan, Paige Griffith, Marina Baretti, Won Jin Ho, Ihab Kamel, Mark Yarchoan, David Hsiehchen
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (7): 1312–1317.
https://doi.org/10.1158/2767-9764.CRC-23-0072
Published: 20 July 2023
View article titled, Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
Open the PDF for Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis

Stefano Testa, Nam Q. Bui, Kristen N. Ganjoo
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (7): 1212–1223.
https://doi.org/10.1158/2767-9764.CRC-23-0139
Published: 12 July 2023
View article titled, Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis
Open the PDF for Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis in another window
Includes: Supplementary data
Journal Articles

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib

Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, Shunsuke Kondo, Kan Yonemori, Kohei Shitara, Satoshi Shiono, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Takuya Suzuki, Takao Takase, Shuya Takashima, Kohei Yamaguchi, Taro Semba, Noboru Yamamoto
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (7): 1189–1199.
https://doi.org/10.1158/2767-9764.CRC-22-0401
Published: 10 July 2023
View article titled, Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
Open the PDF for Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib in another window
Includes: Supplementary data
Journal Articles

Multi-institutional Prognostic Modeling in Head and Neck Cancer: Evaluating Impact and Generalizability of Deep Learning and Radiomics

Michal Kazmierski, Mattea Welch, Sejin Kim, Chris McIntosh, Katrina Rey-McIntyre, Shao Hui Huang, Tirth Patel, Tony Tadic, Michael Milosevic, Fei-Fei Liu, Adam Ryczkowski, Joanna Kazmierska, Zezhong Ye, Deborah Plana, Hugo J.W.L. Aerts, Benjamin H. Kann, Scott V. Bratman, Andrew J. Hope, Benjamin Haibe-Kains
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 1140–1151.
https://doi.org/10.1158/2767-9764.CRC-22-0152
Published: 29 June 2023
View article titled, Multi-institutional Prognostic Modeling in Head and Neck Cancer: Evaluating Impact and Generalizability of Deep Learning and Radiomics
Open the PDF for Multi-institutional Prognostic Modeling in Head and Neck Cancer: Evaluating Impact and Generalizability of Deep Learning and Radiomics in another window
Includes: Supplementary data
Journal Articles

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Michael Cecchini, Janie Y. Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M. Stein, Jeremy Kortmansky, Kimberly L. Johung, Ranjit S. Bindra, Patricia LoRusso, Kurt A. Schalper
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 1132–1139.
https://doi.org/10.1158/2767-9764.CRC-23-0045
Published: 28 June 2023
View article titled, Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Open the PDF for Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A. Boerner, Diane E. Durecki, Joseph P. Eder, Kurt A. Schalper, Alice P. Chen, Patricia LoRusso
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 1113–1117.
https://doi.org/10.1158/2767-9764.CRC-22-0485
Published: 26 June 2023
View article titled, NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
Open the PDF for NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma

Elizabeth R. Kessler, Eryn Callihan, Junxiao Hu, Corbin Eule, Geetika Srivastava, Douglas J. Kemme, Praveena Iruku, Vishal Rana, James Moore, Steven R. Schuster, Mali Amirault, Thomas W. Flaig, Elaine T. Lam
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 1004–1012.
https://doi.org/10.1158/2767-9764.CRC-23-0060
Published: 08 June 2023
View article titled, A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
Open the PDF for A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer

Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 991–1003.
https://doi.org/10.1158/2767-9764.CRC-23-0137
Published: 07 June 2023
View article titled, Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1<sup>+</sup>CD8<sup>+</sup> T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Open the PDF for Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1<sup>+</sup>CD8<sup>+</sup> T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy

Vasu R. Sah, Henrik Jespersen, Joakim Karlsson, Lisa M. Nilsson, Mattias Bergqvist, Iva Johansson, Ana Carneiro, Hildur Helgadottir, Max Levin, Gustav Ullenhag, Anders Ståhlberg, Roger Olofsson Bagge, Jonas A. Nilsson, Lars Ny
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (5): 884–895.
https://doi.org/10.1158/2767-9764.CRC-22-0490
Published: 18 May 2023
View article titled, Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
Open the PDF for Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy in another window
Includes: Supplementary data